The range includes:
Fluodrop (the first fluorescein product specifically designed for veterinary use)
Ocryl - an ocular and periocular cleanser that can also be used to reduce and prevent unsightly tear staining
Ocular lubricants (carbomer and hyaluronic acid based)
Clerapliq – a novel molecule to the UK veterinary market that is used to help restore and regenerate the corneal extracellular matrix
The products will be supported with a selection of materials to help vets, nurses and pet owners in the maintenance of corneal health, including diagnosis and treatment guidelines, anatomical guides, posters and client educational and treatment aids to help with compliance.
William Peel MRCVS, product manager at TVM-UK said: "Our Corneal Focus Range is an exciting way to expand on our product portfolio following the successful introduction of our ‘Anti-tox’ range.
"With ‘Anti-tox’ we successfully managed to make vets and nurses lives easier by providing education and materials alongside a great range of products to help when dealing with poisoning cases in practice. We also attempted to make clients more aware of the dangers of poisoning in pets.
"We hope to emulate this approach and success with our Corneal Focus Range – by developing a wealth of materials for vets, nurses and clients to aid them in managing and understanding ophthalmology cases – and by providing quality products."
TVM UK will be showcasing its new products and support services at the London Vet Show (stand P40) this November.
For more information, visit: http://www.tvm-uk.com/
Current World Organisation for Animal Health (OIE) recommendations are to include a representative strain from each of the two sublineages of equine influenza virus (EIV) - Florida Clade 1 and Florida Clade 2, to deliver optimum protection.
MSD's study was designed to evaluate the efficacy of Equilis Prequenza, containing whole virus Newmarket/2/93 (European strain) and South Africa/4/03 (Clade1) EIV strains, and an HA canarypox vectored vaccine containing Florida Clade 1 and Clade 2 strains.
Two groups of seven Fjord ponies were vaccinated twice, 4 weeks apart (V1 on day 0 and V2 on day 28). One group was vaccinated with Equilis Prequenza (MSD AH) and one group with ProteqFlu (Boehringer Ingleheim). The protective antibody response was measured and ponies were challenged, along with six unvaccinated control ponies, by experimental infection with Wexford/14 (a heterologous clade 2 strain), 1 20 days (4.5 months) after V2, and clinical signs and virus shedding monitored. EI serology was measured by single radial haemolysis (SRH) and hemagglutination inhibition (HI). Clinical signs and virus shedding (measured by qRT-PCR and egg titration) were compared between groups and with controls.
Vicki Farr, BVetMed MRCVS, equine veterinary advisor at MSD Animal Health said: "Following challenge at 120 days after V2 with Wexford/14, this study demonstrates that both vaccines provide a highly significant degree of protection against clinical signs of EI and viral shedding compared to unvaccinated controls. Although the study was not designed to compare the efficacy of the two vaccines, because of practical limitations on the number of animals and hence low power, there was no evidence of any significant differences between these two groups. There was, however, a trend towards slightly lower clinical score on days 4-8 and reduced virus excretion on days 2-5 in the Equilis Prequenza group compared to the HA canarypox vectored vaccine.”
MSD says Equilis Prequenza offers a broad based approach to immunogenicity by addressing and adapting key areas of an equine influenza vaccine - Matrix-C adjuvant, whole virus antigen and strain; efficacy has been proven through challenge trials and longer term protection confirmed by serology.
Vicki added: "Equilis Prequenza addresses key factors involved in promoting effective immunogenicity. It combines the demonstrated efficacy against challenge, with a current circulating strain with an established safety profile. Equilis Prequenza stimulates active immunity against EI providing the reassurance your clients demand. MSD Animal Health is committed to working with equine practices to improve vaccination rates in at-risk horses."
For more information about the trial results contact your MSD Animal Health account manager.
The scheme, which is part of the company's Keeping Britain’s Horses Healthy campaign, includes a pack - endorsed by BEVA and World Horse Welfare - to help yard owners and vets educate owners why they should vaccinate and the benefits of preventative healthcare.
The Yard Excellence Scheme pack includes information on vaccination, weight management, worming and biosecurity. It also helps yard owners implement a range of preventative protocols covering things like worming, vaccination and managing new arrivals, and also put infectious disease outbreak protocols in place.
There are also various things to promote the scheme within the yard, such as yard posters, a horse owner checklist, horse records and responsible horse owner booklets.
All the yards that develop and implement appropriate protocols, in collaboration with their vet, will achieve the Keeping Britain’s Horses Healthy Yard Excellence Scheme Standard and will be promoted on the scheme's Facebook page (@keepinghorseshealthy).
Yards can also promote their achievement via social media and on their website.
Fieke Bennett, equine business manager at MSD Animal Health said: "Our KBHH Yard Excellence Scheme is aimed at encouraging yards and vets to collaborate more closely towards excellent preventative healthcare practices.
"By encouraging vaccination and other preventative healthcare practices, livery yards will have a healthier population of horses; achieving an environment with happy horses, happy owners, and excellent yard reputation.
"This collaboration supports a strong relationship between the vet and the yard, a healthy yard means owners can enjoy their love of horses without restriction."
For further information talk to your MSD Animal Health Equine Account Manager, ring 01908 685685 or refer to KBHH social media feeds on Facebook page and Twitter (@keepinghorseshealthy).
Dr Crawford sent the email to his client, Mrs X, on 15 July 2014, the day on which Mrs X’s horse was due for insemination using horse semen supplied from a horse in Germany. However, the semen had arrived without the Intra Trade Certificate, a requirement for intra-EU inseminations, and so Dr Crawford proceeded to contact the Department for the Environment, Food and Rural Affairs (Defra) for alternative authorisation.
Just after 4:30pm on that day, Mrs X received a text from Dr Crawford advising her that he had received authorisation from the AHVLA, and would forward to Mrs X the AHVLA authorisation email. It later transpired that that the email had in fact been fabricated by Dr Crawford using an email that he had previously received from the AHVLA regarding another matter.
Dr Crawford faced the following charges:
Fabricating an e-mail purporting to be from the veterinary officer at the AVHLA, authorising use of semen from a horse for insemination, when in fact he had not received such authorisation.
Dishonesty in relation to the e-mail described above.
His conduct gave rise to spread of infectious disease which had the potential to affect equine animal health and welfare in the region.
Dr Crawford admitted the first two charges, but denied that his actions had given rise to the risk of disease.
The Committee found the first two charges proved, and moved on to determine the facts of the third charge. They took into account that Dr Crawford had received verbal confirmation that the semen was safe, and that the health papers had been stamped accordingly. He had not, however, seen a copy of this certificate and so there was no guarantee that the semen was safe to use at the time he sent the fabricated email. On consideration of the facts, the Committee found this charge proved, as Mrs X’s mare could have been infected and subsequently could have adversely affected equine animal health and welfare in the region.
They also found that his entire course of action had fallen far short of what is expected of a veterinary surgeon, and that it amounted to disgraceful conduct in a professional respect.
When determining sanction, the Committee took into account a number of aggravating factors, namely the risk of injury to animals, an element of pre-meditation, a disregard for the role of the AHVLA, impersonating a fellow veterinary surgeon, and intending to deceive a veterinary surgeon as well as a member of the public.
It did also, however, take into account the mitigating factors – that there was no injury to the animal, and that it was a single isolated incident from which Dr Crawford did not stand to make any financial gain.
The Committee therefore decided to order the Registrar to suspend Dr Crawford’s registration for 12 months.
Ian Green, chairing the Committee and speaking on its behalf, said: "The Committee did consider whether to remove Dr Crawford from the Register. However, in light of the significant mitigation in this case, the fact that this was an isolated incident in an otherwise unblemished career, together with his acceptance from the outset that he had been dishonest and his assurance that he would never behave in this way again, the Committee decided that in all the circumstances to remove him from the Register would be disproportionate."
Dr Crawford can lodge an appeal with the Privy Council within 28 days of being notified of the Disciplinary Committee's decision.
The online seminar, which equates to one hour’s CPD, features six UK experts in equine endocrinology, with the objective of supporting equine and mixed practice vets in using the clinical history to guide their interpretation of the basal ACTH test results and subsequent treatment decisions.
The speakers participating in the Equine Endocrine Pioneers Circle are:
Harry Carslake MA VetMB DipACVIM MRCVS: Senior lecturer in equine medicine at the University of Liverpool
Edd Knowles MA VetMB MVetMed DipECEIM MRCVS: Specialist in Equine internal medicine at Bell Equine Veterinary clinic
Professor Cathy McGowan BVSc DipVetClinStud MACVSc PhD DEIM DipECEIM FHEA MRCVS: Head of Department of Equine Clinical Science and Director of Veterinary Postgraduate Education at the University of Liverpool
Dr Nicola Menzies-Gow MA VetMB PhD DipECEIM Cert EM(Int Med) MRCVS: Reader in equine medicine at the Royal Veterinary College
Victoria South MA VetMB CertAVP(EM) DipECEIM MRCVS: Senior assistant at Liphook Equine Hospital
Nicola Steele BVM&S CertAVP(EM) MRCVS: Fyrnwy Equine Clinic and Director of Veterinary CPD (Equine and Large Animal)
The webinar considers when vets should test for PPID and decision-making on the best test to use, how to interpret grey zone results and also how to interpret problematic follow up tests. The experts have different opinions on some of these areas, allowing vets in practice to see the different ways in which cases can be viewed and managed.
These principles are then reinforced by the use of three clinical case scenarios with the patients all having the same basal ACTH result but a different selection of clinical signs.
Liz Barrett, equine business head at Boehringer Ingelheim said: "Since the launch of our Talk About Laminitis initiative in 2012, more than 50,000 horses have benefited from complimentary basal ACTH tests to aid the diagnosis of PPID, however two common areas of uncertainty in interpreting ACTH results still exist. Firstly, the interpretation of borderline, equivocal or ‘grey-zone’ results and when PPID treatment should or shouldn’t be recommended and secondly, the interpretation of follow-up ACTH test results and when to advise altering the treatment dose.
"The Equine Endocrine Pioneers Circle webinar allows vets to update their knowledge on this broad subject area and illustrates that there is often more than one way to approach the diagnosis, treatment and management of the PPID case."
To view the Equine Endocrine Pioneers Circle webinar on the Boehringer Academy visit https://www.boehringer-academy.co.uk/webinar/bil205
Dr Thomason initially denied both heads of charge, but on the third day of the hearing he changed his plea and admitted the charge in its entirety.
The first part of the charge related to the fact that the seller of the horse was a both a client of Dr Thomason’s practice and a personal friend of his, and he therefore had a potential and/or actual conflict of interest.
Dr Thomason did not disclose this professional and personal relationship to the prospective purchaser before the pre-purchase exam.
The prospective purchaser only discovered Dr Thomason’s relationship with the seller when reading the vetting certificate at home, and stated that, in the past, she had had a similar experience in which the horse was then found to be lame. She later found out the extent of the personal relationship, when invited to join the seller on a social media site.
The Committee found that, in this set of circumstances, Dr Thomason should not have undertaken the pre-purchase exam at all, and, at the very least, disclosed his personal and professional relationship with the vendor.
The Committee also found that although Dr Thomason did have a system in place to inform any prospective purchasers if the vendor was a client of his practice, this failed to work on this occasion and neither the practice nor Dr Thomason told the prospective buyer that the seller was a client before booking the pre-purchase exam. Dr Thomason had no similar system in place to disclose any close friendships with sellers.
Dr Thomason did not consider there was a conflict of interest as he felt confident he could carry out the pre-purchase exam impartially. In addition, it was his belief that the seller had been alerted to the conflict through a system in place at his practice, implemented to safeguard against this type of error. He stated that he in no way attempted to hide his relationship with the seller to the prospective purchaser.
It was not alleged that Dr Thomason had acted dishonestly.
Ultimately, the Committee found Dr Thomason not guilty of disgraceful conduct in a professional respect.
Ian Green, chairing the Committee and speaking on its behalf, said: "Whilst the Committee concluded that the respondent’s view of his obligations to disclose both the professional and personal relationships he had with the vendor was mistaken, it did not find any improper motivation on his part. It has already noted that he sought to disclose to the prospective purchaser through his system the fact that the vendor was a professional client of his.
"The Committee has weighed all these matters very carefully. It is for the client to determine whether or not to proceed with a PPE when in possession of all relevant facts in relation to any potential conflict of interest, and not for the veterinary surgeon to decide. The autonomy of the client must be respected. The Committee was firmly of the opinion that a failure to comply with the Code is very serious. However, taking into account the particulars of this case, the Committee does not consider that the actions of the respondent amount to disgraceful conduct in a professional respect."
EnteroZoo is a dietary supplement composed of organic mineral and purified water in a gel suspension. Enteromed says it works by binding bacterial toxins as it passes through the animal's digestive tract, thereby helping to maintain a healthy gut and intestinal balance.
Enteromed says that compared to old classic adsorbents, such as clay or charcoal, EnteroZoo can be used long-term and is gentle on an animal's intestines.
The company points to a new in-vitro study from Brighton University School of Pharmacy & Biomolecular Sciences which has shown that EnteroZoo adsorbs E. coli, Shigella and C. difficile toxins1 – common causes of gastrointestinal infection and diarrhoea.
EnteroZoo is suitable for all animals including pregnant and nursing females. It is tasteless and odourless and the company says animals generally accept it without any problems. It can be administered in various ways: directly into the mouth, mixed into feed, put on a treat, mixed in an appropriate amount of water or administered with a plastic syringe into the oral cavity.
For more information, contact: enterozoo@enteromed.co.uk, or visit: www.enterozoo.co.uk
Reference
Equitop GLME is a palatable, pearl formulation joint supplement developed to support the healthy function of cartilage, joint capsules, tendons and ligaments. It is derived from an active extract of New Zealand Green Lip Mussels - a natural source of glucosaminoglycans (GAGs), chondroitin and essential fatty acids – and is tested free of prohibited substances.
Boehringer says the nutrients in Equitop GLME help to lubricate joints, as well as supporting normal joint function, the stability and elasticity of ligaments and the shock-absorbing properties of cartilage.
Equitop GLME is fed once a day either separately or mixed with feed and one tub will typically last for 30 days and can be used in all horses and ponies.
Dr Amy Scott, brand manager for Equitop GLME at Boehringer Ingelheim, said: "By encompassing Equitop GLME into the Equitop portfolio and launching easy-to-read new packaging, we are enhancing our product offering to both veterinary practices and horse owners."
For more information, contact your Boehringer account manager.
The BEVA has welcomed the news, whilst expressing its concern that the drug was suspended without consultation with the veterinary profession in the first place.
Jon Pycock, BEVA President said: "It remains a concern to BEVA that this mechanism was not put in place before the suspension of flunixin was imposed. Contrary to assertions by the VMD, wholesalers were unable to meet the demands of the veterinary profession and clinical use of this medicine was disrupted within 24 hours of the VMD’s initial announcement.
"We are surprised by the Regulator’s lack of awareness of availability in the supply chain and question why there was no consultation with the veterinary sector before the suspension was enacted. The VMD has been aware of this issue since March 2018 and it appears that no contingency was put in place to consider the animal welfare impact of this decision until it was too late."
BEVA Junior Vice President and Specialist in Equine Surgery Tim Mair continued: "Flunixin is a unique medicine in managing pain and sepsis in horses with colic. The VMD appeared to believe that this medicine could be substituted for other veterinary medicines and this is simply not the case. The release of stock from manufacturers is a short-term solution and, looking forward, we would like assurances that the VMD will fast track applications for the modification of product licenses to ensure that equine vets have continued access to these products."
Professor Kate White, Senior Vice President of the Association of Veterinary Anaesthetists added: "Provision of pain relief is essential to maintain animal welfare. The loss of these products would hinder the work of vets working with horses and donkeys and in zoos where they are first line drugs for the management of pain. Use of flunixin in these animals can be undertaken safely with no impact on human health."
Stock of flunixin held by manufacturers will be distributed alongside a ‘caution in use’ letter that will explain the restricted use of this product. BEVA is reminding all equine vets that the horse’s food chain status must be checked when using this product – either using the paper passport or the recently launched chip checker on the central equine database website.
This multimillion pound centre will support the provision of advanced first opinion and referral equine services in the Midlands.
Senior Partner Richard Stephenson said: "It was a great honour and pleasure to have His Royal Highness visit our new premises, and our staff eagerly anticipated meeting Prince Charles and showing him the wonderful facilities we now have."
Amongst these are a Fujifilm SonoSite Edge II portable ultrasound system. Richard added: "Pool House is a well-known practice – we’ve been in existence for over 150 years – and we have developed a reputation as a specialist equine imaging centre, with radiography, ultrasound and MRI capabilities. The new facility has been designed to give us increased theatre capacity and stabling, and we needed an additional ultrasound system to match this expansion."
"The demands of equine practice mean that ultrasound is often required in difficult circumstances, and we need systems that can cope with extreme temperatures, dust, straw, mud, water and the occasional knock. Many pieces of equipment used in veterinary medicine were originally intended for a human clinical environment, so can’t stand up to the rigors of our work – they’re simply not fit for purpose. However, SonoSite systems are perfect for us; they’re robust, highly portable and very intuitive to use, which is important for intermittent ultrasound users."
All bar one of the suspended drugs contain the NSAID flunixin. The other affected drug is the antibiotic, Tribrissen:
Allevinix 50 mg/ml Solution for Injection for Cattle, Pigs and Horses (Ceva Animal Health)
Cronyxin Injection, 5% w/v Solution for Injection, for cattle and horses (Cross Vetpharm Group Ltd)
Finadyne 50 mg/ml Solution for Injection for cattle, pigs and horses (Intervet UK Ltd)
Flunixin 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (Norbrook Laboratories Limited)
Meflosyl 5% Solution for Injection for horses and cattle (Zoetis UK Limited)
Norixin 5% Solution for Injection for cattle and horses (Norbrook Laboratories Limited)
Pyroflam 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (Norbrook Laboratories Limited)
Tribrissen 48% Suspension for Injection for horses, pigs and cattle (Intervet UK Ltd)
The British Equine Veterinary Association says that the decision to suspend the drugs was taken without consultation with the veterinary profession, and is urging the VMD to overturn the suspension in horses not destined for the human food chain, to reduce the potential impact on equine welfare.
Jonathan Pycock, BEVA president said: "BEVA is fully supportive of all attempts to promote food safety, however flunixin is widely viewed as the gold-standard pain killer in horses and is commonly used in horses undergoing both elective and emergency surgery, for the crippling pain associated with laminitis and for severe forms of colic.
"BEVA is calling on the VMD to immediately enable limited batch release of flunixin for use in horses not destined for the human food chain in the interests of animal welfare. The equine veterinary profession has always been open to consultation with the VMD on a range of important matters relating to responsible medicine use, antibiotic resistance, horse identification, passports and the horse meat issue. BEVA is perplexed as to why the VMD failed to consult with the equine veterinary industry on the animal welfare impact of withdrawing such an important drug.”
The Care About Cushing’s website is designed to give horse owners the information they need to spot the signs of Cushing's, thereby prompting diagnosis by their veterinary surgeon.
The online resource includes monitoring tools, personalised alerts, owner guides and webinars. It also offers downloadable self-assessment checklists on Cushing’s disease and laminitis to take owners through the signs to look out for.
Owners whose horses have been diagnosed with Cushing’s are encouraged to sign up as a Care About Cushing’s member to keep up-to-date with the latest information about the disease and create a personal profile for their horse in order to monitor progress. One of the membership benefits is an 'ask the expert' section where members can ask questions about Cushing’s disease and laminitis.
The Care About Cushing’s resource supports Boehringer’s ‘Talk About Laminitis’ initiative to raise awareness of the signs of laminitis and its link with Cushing’s disease.
Talk About Laminitis now runs throughout the year and as part of the campaign the laboratory fees for the blood test which detects Cushing’s (the basal ACTH test) are free.
Liz Barrett, equine business head at Boehringer, said: "Our Talk About Laminitis disease awareness initiative has been hugely successful in highlighting the link between laminitis and Cushing’s disease and helping to diagnose Cushing’s. So much so that Cushing’s is now in the top five equine diseases recorded in the UK1."
For further information on Talk About Laminitis or Care About Cushing’s, visit www.talkaboutlaminitis.co.uk, www.careaboutcushings.co.uk or contact your local Boehringer territory manager.
NEV was first identified in 2013 by veterinary surgeon Dr Isabel Fidalgo Carvalho, who went on to found Equigerminal to develop a commercially viable NEV diagnostic test that can be used by veterinary surgeons, vet labs and horse owners.
Isabel says that NEV - the equine equivalent of HIV - is often misdiagnosed or hidden by other diseases that induce similar symptoms, like anaemia and neurological issues in horses. It is most commonly confused with the Swamp Fever virus (EIAV) and Equine Herpesviruses (EHV).
Indeed, when they tested a number of horses with anaemia, Equigerminal researchers first believed they had found the presence of a divergent strain of the Swamp Fever Virus (EIAV) - because the horses cross reacted with EIAV, but were negative in the official tests. Subsequent research found they were actually suffering from NEV.
Equigerminal says it is believed that NEV is present in up to 10% of horses. Isabel said: "We did test 213 samples from Ireland and found 7% of positive samples for NEV. These Irish horses were horses that usually travel to UK and other locations for sports events."
For the new test, a veterinary surgeon needs to take a blood sample which is sent to the Equigerminal lab.
Isabel says treatment is currently targeted towards improving the general well-being of the horse, health monitoring, and boosting the animal’s immune system. The next stage is to find a treatment, and ideally a cure for NEV. Meantime, Isabel said: “We now need to raise awareness of the problem and help vets to diagnose this disease correctly.”
From October 2020 it will be mandatory for all owners to microchip their horses, ponies and donkeys, or face a fine of up to £200. The new Central Equine Database will then allow local authorities and police to track down the owners of dumped horses and make sure they are punished. It will also mean lost or stolen horses will be reunited with their owners more easily.
Lord Gardiner, Animal Welfare Minister, said: "The government shares the British public’s high regard for animal welfare and it is completely unacceptable that hundreds of horses and ponies are left abandoned every year by irresponsible owners.
"That is why we have today laid new regulations in Parliament requiring horses to be microchipped. This will bolster the ability of local authorities and police to identify abandoned animals, ensuring these beautiful creatures receive the care they deserve and that those who mistreat them will face the consequences."
The BVA has welcomed the move as an important step forward for horse welfare and the integrity of the UK food chain.
British Veterinary Association Senior Vice President Gudrun Ravetz said: "We welcome this announcement to extend compulsory microchipping and believe that the measures represent an important step forward for horse welfare and the integrity of the UK food chain. The one-off cost of microchipping a horse is minimal while the animal welfare benefits in terms of being able to identify lost, stolen, abandoned or fly grazing horses, and identify horses in the face of disease outbreak, as well as the benefits to the integrity of food chain safety, are enormous.
"Universal microchipping of domesticated horses ensures that the legislation has value, the cost of implementing the new Central Equine Database (CED) is not wasted, and that food safety is protected. Together these measures will protect horses, ponies and donkeys from irresponsible owners, help loving owners to be reunited with their animals and keep the food chain free from potentially contaminated horse meat."
The regulations for the database were laid in Parliament today and, subject to parliamentary approval, will come into force on 1 October 2018.
In the trial, published in the Equine Veterinary Journal, synovitis was induced in the right intercarpal joint of 24 horses by intra‐articular injection of 0.5 ng lipopolysaccharide (LPS) of Escherichia coli. After intra‐articular challenge, the nutraceuticals resulted in significantly lower synovial fluid TP, TNCC and PGE 2 compared with placebo, leading the authors to conclude that: "The preventive administration of these nutraceuticals showed anti‐inflammatory effects in this validated synovitis model."
Dr Maarten Oosterlinck DVM, PhD, Dipl. ECVS, one of the authors of the study, said: "Nutraceuticals are often used in the management of osteoarthritis, which is a common cause of chronic lameness in horses but their 'curative' efficacy remains controversial and the quality of the relevant studies is generally low. We set out to evaluate ArtiTec in a well-designed and controlled study. Our research shows that ArtiTec significantly decreased joint inflammation and could be useful in preventing the onset of arthritis."
Cavalor also points to a further field trial of the product by vets in Belgium which showed that it improved lameness in 74% of cases.²
ArtiTec contains glucosamine, MSM, chondroitin, hyaluronic acid, blackcurrant extract, feverfew and pineapple, turmeric root and Boswellia Serrata.
Lieselot Hamerlinck, managing partner at Cavalor said: "Joint supplements account for 34% of the equine supplement market so we know how important these products are to horse owners. Cavalor ArtiTec is the result of an extensive research and development programme and its anti-inflammatory effect has been documented in both scientific studies and a field trial. It can also be used in combination with our other joint supplements, Arti Matrix and Arti Base."
For more information, contact Zebra Products on 01352 763350.
References
Jon Pycock, President of BEVA said: "A significant number of BEVA members have young children and we want to make it as easy as possible for them to enjoy Congress without having to worry about making separate plans for childcare at home. We have already had a great response to the idea and it’s looking like the crèche is going to be very popular."
The theme of this year's Congress is helping horse vets celebrate the benefits and pleasures of their job.
In addition to the social and scientific programme at Congress, there will be special sessions on reproduction, non-clinical aspects of being a vet, succession planning, a moral maze debate on specials manufacturing and role play demonstrations on how to manage difficult situations in practice.
Dr Juan Samper, Associate Dean for students and instruction at the University of Florida College of Veterinary Medicine will be giving the plenary lecture on the challenges and opportunities in equine practice.
There will also be specific lecture streams for veterinary nurses, equine dental technicians and farriers.
For more information on the BEVA Congress crèche or to reserve your child's place, contact Jocelyn@beva.org.uk or call 01638 723558. BEVA says places are limited so early booking is advised.
The BEVA Congress programme can be viewed at www.bevacongress.org.
The ten-minute online survey aims to gather a snapshot of horse health over the period of a week.
The results help to identify trends in endemic equine diseases and help the Blue Cross steer equine awareness, education and research.
This year the survey includes some welfare questions to help guide knowledge in response to what the charity calls 'the UK’s horse welfare crisis'.
The National Equine Health Survey is run by the Blue Cross in partnership with the British Equine Veterinary Association. Dodson and Horrell is helping to cover the costs of running the scheme.
Supporters of the survey include the British Horse Society, Horse Trust, Redwings and the Pony Club.
Medal-winning riders Mary and Emily King, and Yazmin Pinchen (pictured right) also support the survey.
Visit www.bluecross.org.uk/NEHS or email NEHS@bluecross.org.uk to register and take part, which carries the chance of winning prizes including Star Lister Clippers, a Lister Adagio Trimmer and some Burford Ariat boots.
The first charge was that in April 2016, having examined a horse named Alfie on behalf of his owner, Mr Villar gave an opinion to the potential buyers but failed to make it clear that he had not undertaken a pre-purchase examination; failed to declare to the buyer that he had a conflict of interest with regard to the owner; and, failed to explain the pre-purchase examination process to the buyers.
The second charge was that, in July 2016, during a telephone conversation with the buyer, Mr Villar was dishonest and failed to provide clear and accurate information because he told the buyers that he had only been asked to trot Alfie to check he was sound when he had, in fact, carried out a more substantial examination.
The third charge was that Mr Villar had offered to either the owner or the buyer, or both, that he would prepare a veterinary insurance certificate in relation to Alfie when he knew he did not have sufficient records (eg the microchip or passport number) to do so.
The fourth charge was that Mr Villar failed to respond adequately to communications from the buyers about Alfie.
The Committee found that Mr Villar had not in fact carried out a pre purchase examination (“PPE”) and referred to guidance from the British Equine Veterinary Association which identified that pre-purchase examinations are carried out on behalf of buyers. It noted that in this case, Mr Villar had undertaken an examination on behalf of the owner. Accordingly, it did not find that Mr Villar had failed to explain the PPE process to the potential buyers.
However, the Committee did find that Mr Villar had failed to declare that he had a conflict of interest in regards to Alfie’s owner. The Committee said that Mr Villar should have told the buyer that he had been acting on behalf of the owner and was not a neutral party in the potential sale.
The Committee found all aspects of the second charge not proven, on the basis that it was not satisfied so as to be sure that Mr Villar had told the potential buyers that he had only been asked to trot Alfie and check that he was sound.
The Committee found all aspects of the third charge proven on the basis that, in an email sent to the College in March 2016, Mr Villar admitted that he did not have the sufficient records to prepare a veterinary insurance certificate.
The Committee found the fourth charge not proven on the basis that the buyers were not his clients. The Committee therefore concluded that he had no obligation to respond to them, and indeed could not do so in certain respects in order to preserve the confidentiality of his client.
The Committee then determined that the charges found proven, when taken individually or in combination, did not amount to serious professional misconduct.
Ian Green, chairing the Committee and speaking on its behalf, said: "The following mitigating factors were present in this case: the circumstances of the incident, the fact that there was no premeditation, the fact that he was requested by his client to advance an opinion to [the buyers] concerning Alfie and that his ill judgement was on the spur of the moment and the fact that he had no financial gain. These are all important factors. Likewise, the fact that he did not know that the [buyers] regarded him as their pre-purchase examination vet is an important matter.
"The respondent’s conduct was clearly against the principles of behaviour articulated by Mr Morley [who acted as an expert witness for the College] in his expert report and in his evidence. Nevertheless, the Committee does not find that in the particular circumstances of this case, namely being asked to speak to a potential purchaser without warning and without being made aware of the contractual arrangements which had been made between the respondent and [the owner], the respondent should not properly be the subject of a finding of disgraceful conduct in a professional respect."
The company warned last year that Equip Artervac would be out of stock from the end of November 2017 until mid-2018, but says that the re-availability of the vaccine means many vaccinated stallions and teasers should now be able to have their six-monthly booster dose within the normal designated timeframe.
Equip Artervac is indicated for the active immunisation for horses against equine arteritis virus to reduce the clinical signs and shedding of virus in nasal secretions following infection.
For further information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
The National Equine Health Survey is a snapshot survey, conducted by the Blue Cross in conjunction with the British Equine Veterinary Association during the month of May each year, sponsored by Dodson & Horrell and Zoetis. Last year 5,235 people took part and returned records for 15,433 horses.
The 2017 survey found that 39% of those who carry out faecal worm egg counts do so at four-monthly intervals, 22% do so at 8-12 week intervals and 2% do so at six-weekly intervals.
Dr Wendy Talbot, equine vet at Zoetis said: "The NEHS results show that there’s still a lack of understanding about the purpose and benefits of FWECs during the grazing season. For the most effective results FWECs should be conducted every 8 to 12 weeks between March and October. They will indicate which horses are passing the most worm eggs in their droppings and mean that horses are only treated when necessary.2 Remember though that FWECs don’t remove the need to treat horses at specific times of year for encysted small redworm, tapeworm and bots, none of which will show up in FWECs.3"
References:
This, says Spillers, suggests that older horses, whether or not they have been diagnosed with insulin dysregulation, need an appropriate diet and management plan to help minimise the risks associated with insulin dysregulation such as laminitis.
The two studies1,2, which were conducted in collaboration with Michigan State University, aimed to find out more about the relationship between insulin dysregulation, dietary adaptation, and ageing to help guide more appropriate feeding regimens for senior horses.
Both studies investigated tissue insulin resistance and the insulin response in healthy adults compared to healthy senior horses adapted to diets with varying levels and sources of hydrolysable and structural carbohydrate (starch, sugar, and fibre).
Results from both studies showed insulin responses tend to increase with age in healthy horses, regardless of the diet they had been fed prior to evaluation. The insulin response, for example, was highest in the senior horses fed a starch rich meal even when they had been adapted to such a diet.
Clare Barfoot, RNutr, the research and development manager at Spillers said: "These studies confirm that even healthy older horses can have an increased insulin response compared to younger animals.
"This suggests that the energy sources used in the diet of senior horses and their effect on insulin dynamics need to be carefully considered.
"Practically, this means restricting the overall amount of starch and sugar in the diet especially for those horses that already have additional risk factors such as obesity, native breeding or PPID."
Dr Neil Bryant from the AHT, who is leading the research, said: "EHV is a major welfare concern for horses and foals and causes emotional, as well as financial strains, on horse owners and breeders around the world. It can strike any horse at any time so a vaccine will be of global welfare benefit to all horses, including the thoroughbred and sports horse breeding industries, and would help control this serious and sometimes fatal disease."
As a viral infection, EHV can cause respiratory disease, abortion or fatal illness in new born foals and neurological disease in adult horses, with signs ranging from slight wobbliness through to complete paralysis. The disease can strike any horse at any time because the virus, like other herpesviruses (such as the cold sore virus in humans), becomes dormant within most horses early in their life. It then re-emerges when the animal is later stressed such as when transported or mixed with new horses. A seemingly healthy pregnant mare may suddenly, and without warning, abort her unborn foal or may show signs of respiratory disease including mild fever, coughing and discharge from the nose. A horse which appears fit and well may suddenly show abnormalities when walking and within hours may be unable to stand.
Despite the potential severity and impact of outbreaks, there is still no vaccine that is licensed to protect against the neurological form of the disease and abortions still occur in highly vaccinated horse populations. The AHT says protection afforded by existing vaccines currently in use is sub-optimal, something that was highlighted by the 2016 abortion storm in Hertfordshire in fully vaccinated animals.
Neil added: "We have become aware of a pressing need for progress towards a new and improved EHV-1 vaccine. Just last month, the AHT was again called upon to work with the racing industry and affected parties in dealing with confirmed cases of EHV-1 abortion in premises in Yorkshire and Suffolk."
To that end, the charity has now established the Equine Industries EHV Vaccine Steering Group. Chaired by Professor Joe Brownlie of the RVC, the steering group includes world-renowned experts on both human and equine herpes viruses from a number of research establishments, who have concluded that the most appropriate way forward is for the AHT to design a modified live virus (MLV) vaccine.
After securing funding from a large number of organisations, including the Alborada Trust, EBM Charitable Trust, Horserace Betting Levy Board and the Racing Foundation, Paul Mellon Estate, Thompson Family Charitable Trust, Coolmore Ireland, Newsells Park Stud, Thoroughbred Breeders’ Association and Juddmonte Farms, the AHT has begun its five-year research programme.
Neil added: "We’re at the beginning of a very exciting and potentially ground-breaking vaccine development. Through our research, we will construct different viruses with attenuating mutations and assess their suitability as MLVs. We hope our findings will enable further development by vaccine manufacturers in creating an effective vaccine to protect against the serious clinical signs induced by EHV-1."
Jon (pictured right, in blue) has devised the fundraising event as part of his BEVA Presidential year. He has put together three routes in Yorkshire to suit all abilities, over the same roads used by Ron Kitching, the champion 1930s road racer. Each route starts and finishes at York racecourse and will be supported with signage and feed and watering stops along the way.
Participants can choose from a 35 mile largely flat 'trot' which takes in the city of York, a 66 mile slightly hilly 'canter' skirting the Yorkshire Wolds and a 91 mile 'gallop' over the Rosedale Chimney, which, according to Jon has "enough ascent to make Sir Chris Bonnington happy!"
There will also be a short family ride on the afternoon of 2nd June so that children and less practised cyclists can get involved.
To enter visit http://www.wheelsinwheels.com/BEVA_Presidents_challenge_Sportive_UK.php
For further information visit www.beva.org.uk
The new briefing will summarise the latest veterinary innovations, resources and research which are of practical value to vets in practice. In other words, only what you strictly need to know.
Need to Know content will be curated by three practising veterinary surgeons: Liz Barton MRCVS (Small Animal, pictured right), Aoife Byrne MRCVS (Equine), and Rachel Tennant MRCVS (Farm Animal). It replaces InDigestion, VetSurgeon.org’s previous monthly newsletter which only linked to the most popular content on the site itself. By contrast, Need to Know summarises developments from all sources.
VetSurgeon.org Editor Arlo Guthrie said: "In these days of information overload, our aim here is to provide busy veterinary surgeons with a really succinct summary of anything that really matters, wherever it comes from."
Need to Know is the result of a new partnership between VetSurgeon.org and Vetsnet, a veterinary wellbeing resource hub set up by Liz to support her colleagues in the profession, and the bulk of any additional advertising revenue generated by the initiative will be ploughed back into Vetsnet.
Arlo added: "Since VetSurgeon launched back in 2008, content has been entirely curated by me. I like to think that has worked reasonably well. Still, having practising veterinary surgeons involved editorially is a big step forward in making sure our content is always useful and relevant."
Anyone subscribed to receive emails from VetSurgeon.org on registration will automatically receive Need To Know.
If you have subscribed, but are NOT receiving emails from VetSurgeon.org, you usually need to log into your email account online and move emails from VetSurgeon.org from your spam or junk folder into your inbox. Some email providers (notably Hotmail) also allow you to ‘whitelist’ emails from certain people and organisations. In that case, add 'vetsurgeon.org' to your whitelist.
If you have unsubscribed from emails from vetsurgeon.org in the past and now want to resubscribe, email support@vetsurgeon.org and we’ll remove you from the exclusion list.